Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine

European Psychiatry

Volumn 25, Issue 8, 2010, Pages 476-478

  Benedetti, F ^a   Dallaspezia, S ^a   Colombo, C ^a   Lorenzi, C ^a   Pirovano, A ^a   Smeraldi, E ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Antidepressant; COMT; Dopamine; Fluvoxamine; Noradrenaline; Serotonin

Indexed keywords

CATECHOL METHYLTRANSFERASE; FLURAZEPAM; FLUVOXAMINE; METHIONINE; VALINE;

ADULT; ARTICLE; CATECHOLAMINERGIC SYSTEM; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; GENOTYPE; HAMILTON SCALE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR DEPRESSION; MALE; MONOTHERAPY; NEUROTRANSMISSION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ALLELES; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CATECHOL O-METHYLTRANSFERASE; DEPRESSIVE DISORDER; FEMALE; FLUVOXAMINE; GENE FREQUENCY; GENOTYPE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78649968354     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2009.12.007     Document Type: Article

References (25)

1. Arias B., Serretti A., Lorenzi C., Gasto C., Catalan R., Fananas L. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord 2006, 90:251-256.
2. Baune B.T., Hohoff C., Berger K., Neumann A., Mortensen S., Roehrs T., et al. Association of the COMT val158met variant with antidepressant treatment response in major depression. Neuropsychopharmacology 2008, 33:924-932.
3. Benedetti F., Barbini B., Bernasconi A., Fulgosi M.C., Dallaspezia S., Gavinelli C., et al. Acute antidepressant response to sleep deprivation combined with light therapy is influenced by the catechol-O-methyltransferase Val(108/158)Met polymorphism. J Affect Disord 2010, 121(1-2):68-72.
4. Benedetti F., Colombo C., Pirovano A., Marino E., Smeraldi E. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology (Berl) 2009, 203:155-160.
5. Faul F., Erdfelder E., Lang A.G., Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007, 39:175-191.
6. Gerstenberg G., Aoshima T., Fukasawa T., Yoshida K., Takahashi H., Higuchi H., et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology (Berl) 2003, 167:443-448.
7. Hill T., Lewicki P. Statistics: methods and applications. A comprehensive reference for science, industry, and data mining. General Linear Models 2006, 245-276. StatSoft, Tulsa (OK), Chapter 18.
8. Kasper S., Dotsch M., Kick H., Vieira A., Moller H.J. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 1993, 3:13-21.
9. Kobayashi T., Hayashi E., Shimamura M., Kinoshita M., Murphy N.P. Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study. Psychopharmacology (Berl) 2008, 197:567-580.
10. Kugaya A., Seneca N.M., Snyder P.J., Williams S.A., Malison R.T., Baldwin R.M., et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology 2003, 28:413-420.
11. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
12. Lucca A., Lucini V., Catalano M., Alfano M., Smeraldi E. Plasma tryptophan to large neutral amino acids ratio and therapeutic response to a selective serotonin uptake inhibitor. Neuropsychobiology 1994, 29:108-111.
13. McCulloch C.E., Searle S.R., Neuhaus J.M. Generalized Linear and Mixed Models 2008, John Wiley & Sons. 2nd Ed.
14. Millan M.J. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006, 110:135-370.
15. Muller K.E., LaVange L.M., Ramey S.L., Ramey C.T. Power calculations for general linear multivariate models including repeated measures applications. J Am Stat Assoc 1992, 87:1209-1226.
16. O'Brien R.G., Muller K.E. A unified approach to statistical power for t-tests to multivariate models. Applied analysis of variance in behavioral sciences 1992, Marcel Dekker, New York. L.K. Edwards (Ed.).
17. Perlis R.H., Fijal B., Adams D.H., Sutton V.K., Trivedi M.H., Houston J.P. Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biol Psychiatry 2009, 65:785-791.
18. Smeraldi E., Zanardi R., Benedetti F., Dibella D., Perez J., Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998, 3:508-511.
19. Smolders I., Clinckers R., Meurs A., De Bundel D., Portelli J., Ebinger G., et al. Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action. Neuropharmacology 2008, 54:1017-1028.
20. Sulzer D., Edwards R.H. Antidepressants and the monoamine masquerade. Neuron 2005, 46:1-2.
21. Szegedi A., Rujescu D., Tadic A., Muller M.J., Kohnen R., Stassen H.H., et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 2005, 5:49-53.
22. Timm N., Kim K. Univariate and Multivariate General Linear Models: Theory and Applications with SAS 2006, Heidelberg Springer, Berlin, Hall/CRC. C, editor. 2nd Ed.
23. Tremblay P., Blier P. Catecholaminergic strategies for the treatment of major depression. Curr Drug Targets 2006, 7:149-158.
24. Tsai S.J., Gau Y.T., Hong C.J., Liou Y.J., Yu Y.W., TJ C. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. J Affect Disord 2008, 113:183-187.
25. Yoshida K., Higuchi H., Takahashi H., Kamata M., Sato K., Inoue K., et al. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. Hum Psychopharmacol 2008, 23:121-128.